Skip to main content

Master of Public Health

Adverse events are rare after single-dose montelukast exposures in children.

AUTHORS

Arnold DH , Bowman N , Reiss TF , Hartert TV , Seger DL , . Clinical toxicology (Philadelphia, Pa.). 2017 6 22; (). 1-5

ABSTRACT

Montelukast sodium is a leukotriene-receptor antagonist approved as a controller medication for chronic asthma and allergic rhinitis in children and adults. We sought to characterize adverse events associated with single montelukast exposures in children ages 5-17 years and to determine whether adverse events were dose related for all-dose and for ultra-high-dose (≥50 mg) exposures.

Montelukast sodium is a leukotriene-receptor antagonist approved as a controller medication for chronic asthma and allergic rhinitis in children and adults. We sought to characterize adverse events associated with single montelukast exposures in children ages 5-17 years and to determine whether adverse events were dose related for all-dose and for ultra-high-dose (≥50 mg) exposures.

Tags: